Fig 1.
Markov model for patients with advanced gastric or gastro-oesophageal cancer.
Table 1.
Log-logistic parameters for Progressive-Free Survival (PFS) and Overall Survival (OS) for two strategies.
Table 2.
Model economic parameters and the range of the sensitivity analysis.
Table 3.
The base-case analysis between mainland China and Beijing City.
Fig 2.
Tornado diagram of the one-way sensitivity analysis of the Incremental Cost-Effectiveness Ratio (ICER) of RAM over chemotherapy in all patients in the mainland China (A) and the Beijing city (B). PD, progressed disease; PFS, Progressed-free disease; RAM, ramucirumab.
Fig 3.
Ramucirumab cost-effectiveness curves under different costs.